<SEC-DOCUMENT>0001140361-25-042598.txt : 20251118
<SEC-HEADER>0001140361-25-042598.hdr.sgml : 20251118
<ACCEPTANCE-DATETIME>20251118161554
ACCESSION NUMBER:		0001140361-25-042598
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251118
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251118
DATE AS OF CHANGE:		20251118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		251494856

	BUSINESS ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20059077_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:insm="http://insmed.com/20251118" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_fa0c056edc20443ea1a2afc88bea3fb3" contextRef="c20251118to20251118" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_138d0cd20e39441fb88994927dcbf81c" contextRef="c20251118to20251118">0001104506</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="insm-20251118.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20251118to20251118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-18</xbrli:startDate><xbrli:endDate>2025-11-18</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div><span style="font-size: 10pt;"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_f3020859e4854f34943dbba5137bd84f" contextRef="c20251118to20251118">8-K</ix:nonNumeric></div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">The Securities Exchange Act of 1934</div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_f635d152cf594bb4acd885577dd7bf6b" contextRef="c20251118to20251118" format="ixt:date-monthname-day-year-en">November 18, 2025</ix:nonNumeric></div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_7784286cc4df42c5991bacd653ccd847" contextRef="c20251118to20251118">INSMED INCORPORATED</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Exact name of registrant as specified in its charter)</div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33.25%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_9ddc2809e82044638c4cb24989f0e675" contextRef="c20251118to20251118" format="ixt-sec:stateprovnameen">Virginia</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_75c397c825214611ba353488c2ff590d" contextRef="c20251118to20251118">000-30739</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 33.25%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_379287efcb8445e887ebbacd57af7fda" contextRef="c20251118to20251118">54-1972729</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33.25%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(State or other jurisdiction of incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(Commission File Number)</div>
            </td>

    <td style="width: 33.25%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_aa46f54c87b843558e6f5274bef11c60" contextRef="c20251118to20251118">700 US Highway 202/206</ix:nonNumeric><br/>
              </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_88d65d06043f44f1bbf38c35f868ef2d" contextRef="c20251118to20251118">Bridgewater</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_7dbcb8eac36f499cb21bdecaf5cbf80c" contextRef="c20251118to20251118" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_9291b8900c2e4f76af739461c54d03b5" contextRef="c20251118to20251118">08807</ix:nonNumeric><br/>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(Address of principal executive offices)</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-size: 10pt; text-align: center;">(Zip Code)</td>

  </tr>


</table>
      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-family: 'Times New Roman'; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_5e7af2288a304fe3bb16995635b2b933" contextRef="c20251118to20251118">908</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_bfb31c89a7f64ab39325eadc00f7d5c2" contextRef="c20251118to20251118">977-9900</ix:nonNumeric></span></div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Not Applicable</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Former name or former address, if changed since last report.)</div>

      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions (see General Instruction A.2. below):</div>

      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_172a2f3b8af84dbc85d95733441b22db" contextRef="c20251118to20251118" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_0d88d05879e94794b3d75b729407ab28" contextRef="c20251118to20251118" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_ac55bbd420e94d75bdcfe80c7d7efd60" contextRef="c20251118to20251118" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_07139530014e43ca9b7f1a538946156e" contextRef="c20251118to20251118" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 37.64%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 24%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 37.54%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Name of each exchange on which </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 37.64%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_d9950c6192464551bbf3336e17e83eda" contextRef="c20251118to20251118">Common Stock, par value $0.01 per share</ix:nonNumeric><br/>
            </td>

    <td style="width: 24%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_4e8c083707934900b5b0afa02760b972" contextRef="c20251118to20251118">INSM</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 37.54%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_173ca36f8adc4617a9501de7067f0159" contextRef="c20251118to20251118" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric><br/>
            </td>

  </tr>


</table>
      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the
        Securities Exchange Act of 1934 (17 CFR 240.12b-2).</div>

      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_ea60a5c1c3254819a39bfb354eabd8bd" contextRef="c20251118to20251118" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: justify;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ITEM 7.01 &#8212;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Regulation FD Disclosure.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">On November 18</span><span style="font-size: 10pt;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, 2025, Insmed Incorporated (the &#8220;Company&#8221;) issued a press release announcing that the European Commission (the &#8220;EC&#8221;) has approved BRINSUPRI<sup>&#174;</sup> (brensocatib 25 mg tablets) for the treatment of non-cystic
            fibrosis bronchiectasis (&#8220;NCFB&#8221;) in patients 12 years of age and older with two or more exacerbations in the prior 12 months. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated
            herein by reference.</span></span></div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the
        Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a
        filing.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ITEM 8.01 &#8212;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Other Events.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">On November </span><span style="font-size: 10pt;">18<span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, 2025, the Company announced that the EC has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12
            months.</span></span></div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ITEM 9.01 &#8212;</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(d)</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Exhibits</span></span></div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 12%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit</div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">No.</div>
            </td>

    <td style="width: 1.39%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 87%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';"><a href="ef20059077_ex99-1.htm">99.1</a></div>
            </td>

    <td style="width: 1.39%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 87%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Press release issued by Insmed Incorporated on November 18, 2025.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">104</div>
            </td>

    <td style="width: 1.39%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 87%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Cover Page Interactive Date File (embedded within the Inline XBRL document).</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">SIGNATURES</span></div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
        undersigned hereunto duly authorized.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Dated: November 18, 2025</div>
            </td>

    <td colspan="2" style="vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">INSMED INCORPORATED</div>
            </td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td colspan="2" style="vertical-align: top; font-size: 10pt;"><br/>
            </td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">By:</div>
            </td>

    <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">/s/ Michael A. Smith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
            </td>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Michael A. Smith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
            </td>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Chief Legal Officer and Corporate Secretary</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
<div><br/></div>

        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    </div>

  </div>

  <div><span style="font-size: 10pt;"> </span></div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20059077_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;"> Exhibit 99.1</font><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center;"><img width="164" height="75" src="image0.jpg"></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">European Commission Approves BRINSUPRI&#8482; (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European
        Union</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">&#8212; Non-Cystic Fibrosis Bronchiectasis (NCFB)<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>Is a Serious,
        Progressive Lung Disease That Can Lead to Permanent Lung Damage &#8212;</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">&#8212; BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation &#8212;</div>
      <div><br>
      </div>
      <div style="text-align: center; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">&#8212; BRINSUPRI Was Reviewed Under EMA&#8217;s Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health &#8212;</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">BRIDGEWATER, N.J., 18 November, 2025 /<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">PRNewswire</font>/ -- Insmed Incorporated (Nasdaq:
        INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the European Commission has approved BRINSUPRI
        (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months. BRINSUPRI is a first-in-class therapy, offering the first and
        only approved treatment indicated for NCFB in the European Union (EU). BRINSUPRI was reviewed under accelerated assessment by the EMA as it is deemed to be of major interest for public health.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">NCFB is a chronic and progressive disease that can lead to permanent lung damage and lung function decline. Unlike other respiratory diseases that are characterized by
        airway narrowing, bronchiectasis causes airways to permanently widen, making it harder to clear mucus and bacteria, leading to persistent inflammation and infection. A hallmark of bronchiectasis is frequent exacerbations, or flares, when
        symptoms&#8212;such as coughing, increased mucus, shortness of breath and fatigue&#8212;worsen. An estimated 600,000 people in the EU are diagnosed with NCFB, with approximately two million additional people potentially undiagnosed.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;Living with non-cystic fibrosis bronchiectasis profoundly alters daily life, taking a toll on both physical health and emotional well-being,&#8221; said ASPEN lead study
        investigator James Chalmers, MBChB, Ph.D., Professor and Consultant Respiratory Physician at the School of Medicine, University of Dundee, UK. &#8220;The European Commission&#8217;s approval represents a major milestone for patients and clinicians in Europe,
        offering a much-needed treatment that can help reduce exacerbations, potentially slow disease progression, and reshape the treatment landscape for this debilitating disease.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This approval is based on a comprehensive scientific evaluation of the marketing authorization application, including data from the Phase 3 ASPEN and Phase 2 WILLOW
        studies, which were both published in the <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">New England Journal of Medicine</font>. In ASPEN, patients taking BRINSUPRI 25 mg had a 19.4% reduction in annual rate of
        exacerbations, as compared to placebo. BRINSUPRI 25 mg also met several exacerbation-related secondary endpoints, including significantly prolonging the time to first exacerbation and significantly increasing the proportion of patients remaining
        exacerbation-free over the treatment period. Patients who received BRINSUPRI 25 mg experienced statistically significant less decline in lung function, as measured by forced expiratory volume in one second (FEV&#8321;) after using a bronchodilator, at
        week 52. The safety of BRINSUPRI was also evaluated in both studies. The most frequently reported adverse reactions are headache (9.2%), hyperkeratosis (5.9%), dermatitis (4.2%), rash (4.1%), upper respiratory tract infections (3.9%), and dry skin
        (3.0%).</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;At Insmed, our mission has always been to bring new therapies to underserved patient communities. With BRINSUPRI, we now have the first treatment for non-cystic fibrosis
        bronchiectasis approved in the European Union&#8212;a historically overlooked population with long-standing unmet medical needs,&#8221; said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. &#8220;The accelerated approval reflects the strength of the
        data and the potential to become the new standard of care for treating patients with non-cystic fibrosis bronchiectasis who had at least two prior exacerbations. We are grateful to the patients, clinicians and partners who made this milestone
        possible.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">The EC approval follows a positive opinion from the Committee for Medicinal Products for
          Human Use of the European Medicines Agency (EMA) on 16 October 2025. </font>Insmed will engage with authorities across the EU to secure access to BRINSUPRI for eligible patients beginning in early 2026.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Applications for brensocatib are currently under review with the Medicines and Healthcare products Regulatory Agency in the U.K. and the Pharmaceuticals and Medical
        Devices Agency in Japan.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About<font style="font-size: 10pt; font-family: 'Times New Roman';">&#8239;</font>BRINSUPRI (brensocatib)</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">BRINSUPRI (brensocatib) is a small molecule, once-daily, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). BRINSUPRI (brensocatib 10 mg and 25 mg tablets) is
        indicated in the United States for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age or older. In the European Union, BRINSUPRI (brensocatib 25 mg tablets) is approved for the treatment of
        NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Brensocatib is designed to inhibit the activation of enzymes (neutrophil serine proteases) in neutrophils that are key drivers of chronic airway inflammation in NCFB.
        Brensocatib is also being evaluated for its potential role in other neutrophil-mediated diseases.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About ASPEN</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">ASPEN was a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic
        fibrosis bronchiectasis (NCFB). As part of the ASPEN study's conduct, more than 460 trial sites were engaged in nearly 40 countries. After excluding sites that did not enrol any patients and all sites in Ukraine, the total number of active sites in
        ASPEN was 391 sites in 35 countries. Adult patients (ages 18 to 85 years) were randomized 1:1:1 and adolescent patients (ages 12 to &lt;18 years) were randomized 2:2:1 for treatment with brensocatib 10 mg, brensocatib 25 mg, or placebo once daily
        for 52 weeks, followed by 4 weeks off treatment. The primary efficacy analysis included data from 1,680 adult patients and 41 adolescent patients.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About WILLOW</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">WILLOW was a randomized, double-blind, placebo-controlled, parallel-group, multi-center, multi-national, Phase 2 study to assess the efficacy, safety and tolerability,
        and pharmacokinetics of brensocatib administered once daily for 24 weeks in patients with non-cystic fibrosis bronchiectasis (NCFB). WILLOW was conducted at 116 sites and enrolled 256 adult patients diagnosed with NCFB who had at least two
        documented pulmonary exacerbations in the 12 months prior to screening. Patients were randomized 1:1:1 to receive either 10 mg or 25 mg of brensocatib or matching placebo. The primary efficacy endpoint was the time to first pulmonary exacerbation
        over the 24-week treatment period in the brensocatib arms compared to the placebo arm.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Bronchiectasis </div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">NCFB is a chronic, progressive, and inflammatory lung disease that causes the airways to become permanently widened due to a cycle of infection, inflammation, lung tissue
        damage, and mucociliary dysfunction. Patients with NCFB often experience repeated exacerbations, requiring antibiotic therapy and/or hospitalizations. Symptoms include chronic cough, excessive sputum production, shortness of breath, fatigue, and
        repeated respiratory infections, which can worsen the underlying disease. An estimated 600,000 people in the EU are diagnosed with NCFB, with approximately two million additional people potentially undiagnosed.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BRINSUPRI&#8482; (brensocatib) U.S. INDICATION AND IMPORTANT SAFETY INFORMATION</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Indication in the U.S.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. </div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Important Safety Information in the U.S.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">WARNINGS AND PRECAUTIONS</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Dermatologic Adverse Reactions</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development
        of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Gingival and Periodontal Adverse Reactions</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups
        while taking BRINSUPRI. Advise patients to perform routine dental hygiene.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Live Attenuated Vaccines</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live
        attenuated vaccines should be avoided in patients receiving BRINSUPRI.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADVERSE REACTIONS</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The most common adverse reactions &#8805;2% in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The
        safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions.<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font></div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Less Common Adverse Reactions</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Liver Function Test Elevations</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg
        and 25 mg arms compared to placebo. The incidence of ALT &gt;3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of AST &gt;3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline phosphatase &gt;1.5X ULN was 2.5%, 4.1%, and
        4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Skin Cancers</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated
        patients.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Alopecia</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10 mg and 25 mg was 1.5% and 1.6% respectively, compared to 0.4% in placebo-treated patients. </div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">USE IN SPECIFIC POPULATIONS</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Pregnancy: </font>There are no clinical data on the use of BRINSUPRI in pregnant women.<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font></div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Lactation: </font>There is no information regarding the presence of BRINSUPRI and/or
        its metabolite(s) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BRINSUPRI and any
        potential adverse effects on the breastfed child from BRINSUPRI or from the underlying maternal condition.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Pediatric use: </font>The safety and effectiveness of BRINSUPRI for the treatment of
        NCFB have been established in pediatric patients aged 12 years and older. Common adverse reactions in pediatric patients aged 12 years and older enrolled in ASPEN were consistent with those in adults. The safety and effectiveness of BRINSUPRI have
        not been established in pediatric patients younger than 12 years of age.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Please see full <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>US Prescribing Information</u></font>.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Insmed</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing
        serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most
        advanced programs are in pulmonary and in&#64258;ammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene
        therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as
        one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Science</font> Top Employer. Visit <u><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">www.insmed.com</font></u> to learn more or follow us on <u><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">LinkedIn</font></u>, <u><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Instagram</font></u>, <u><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">YouTube</font></u>, and <u><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">X</font></u>.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Forward-looking Statements </div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the
        Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates,"
        "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and
        other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in
        any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: failure to successfully commercialize BRINSUPRI in the U.S. or European Union (EU) or to maintain U.S. or EU approval for BRINSUPRI;
        failure to obtain, or delays in obtaining, regulatory approvals for BRINSUPRI in the United Kingdom or Japan, including the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or
        other adverse actions by the applicable regulatory authority; uncertainties in the degree of market acceptance of BRINSUPRI by physicians, patients, third-party payors and others in the healthcare community; inaccuracies in the Company's estimates
        of the size of the potential markets for BRINSUPRI or in data the Company has used to identify physicians; expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company's
        inability to obtain adequate reimbursement from government or third-party payors for BRINSUPRI or acceptable prices for BRINSUPRI; development of unexpected safety or efficacy concerns related to BRINSUPRI, including the risk that data generated in
        further clinical trials of brensocatib may not be consistent with the results of the ASPEN study, which may result in changes to the product label and may adversely affect sales, or result in withdrawal of BRINSUPRI from the market; failure by us
        to comply with agreements related to brensocatib, including our license agreement with AstraZeneca AB; failure to successfully conduct future clinical trials for brensocatib, including due to the Company's potential inability to enroll or retain
        sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things; failure to obtain regulatory approval for potential future brensocatib indications; and failure of third parties on which
        the Company is dependent to manufacture sufficient quantities of brensocatib for commercial or clinical needs, to conduct the Company's clinical trials, or to comply with the Company's agreements or laws and regulations that impact the Company's
        business or agreements with the Company.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature,
        forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company's
        business, please see the factors discussed in Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent Company filings with the Securities and Exchange Commission (SEC).</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company
        disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements
        may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Contact:</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investors</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Bryan Dunn</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Vice President, Investor Relations</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(646) 812-4030</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>investor.relations@insmed.com</u></div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Media</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Claire Mulhearn</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Vice President, Corporate Communications</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(862) 842-6819</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>media@insmed.com</u></div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>insm-20251118.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<xs:schema targetNamespace="http://insmed.com/20251118" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:insm="http://insmed.com/20251118" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20251118_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20251118_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://insmed.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>insm-20251118_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>insm-20251118_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://insmed.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="insm-20251118.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://insmed.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "O 7@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ:TKQ=XF\2^)O!WQ_P!4^T>(9]2A^/.@7.M0_P#"S/[7_P"$O\7.^N:U>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_P=U?\ #1G_ !B'_P!&D?\ %<?\@'_A.O\ DXS]S_R53_FF?_),_P#D@/\
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M:PZ!;VN@>)?B%::3#XNUW1+:W\)^%H(-*U35[JQAA\-:!%' J:-IRVWXI_\
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M/#X:A4Q-:;QN7MTZ-&G*K4FZ<<6ZK<:<9-PC!U';E47+0_J"HK\ _P#@H?\
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MTSPYK_A;PW=>,KGU'_@IE_P5[_9?_P""8?A_0K3XH-K?Q$^-/CK1=7UGX>_
MOP#+I3>*;_3K.VU2WTWQ=XZU/4[R&S^'GPUU+Q38)X5C\57=MK6O:G>C79_
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MW$3P^*6)<Y-U:BI3I5<12G2]G"E"#J>RG3JMPC[12E_-#_P7%_8Q\'?L,_\
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MT33]3:3QG\0M*\+:[#XKM/A7X3\>>(M$@N;C0FCKY$_X-V_^4.G['W_=P/\
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M3/#6MZAIB^(VU;X-Q_#V3Q'X=AU'PK<>)_&OASQ=8^+_ (9Z3^E]U_P:<_\
M!..XE62+XN?MG6*K;V<!AM?B1\%GB>6VM(+::\8WO[/5Y,+G4)HI+^\5)4M$
MN[F=+"UL;!;:RM_Z>:*_F_/?I*>,F=9MB\SI\8X_)Z.(JU)8?*\HC0PN78'#
MRGS4\-0I^QG4JJC%1@L1BZE?%U$FZM>;E*_PN,X[XHQ>)J8B.:5L+&<I<F'P
MW+3H48-WC3A'E;ERI)*=24ZCU;F[N_\ BGU_KM?\$UO^4<_[ ?\ V93^RO\
M^J+\"5_D2U_KM?\ !-;_ )1S_L!_]F4_LK_^J+\"5_5OTX_^25X%_P"R@S+_
M -5T3]&\6_\ D791_P!AM?\ ],(^UJ***_S;/PH**** "BBB@ HHHH ****
M"BBB@ HHHH *_P 4^O\ :PK_ !3Z_P!!/H)_\W3_ .[(_P#?O/VCPA_YJ'_N
MD_\ O3/]03_@W;_Y0Z?L??\ =P/_ *U)\;:^UO\ @I3_ ,HY_P!OS_LRG]JC
M_P!47X[KXI_X-V_^4.G['W_=P/\ ZU)\;:^UO^"E/_*.?]OS_LRG]JC_ -47
MX[K^7>+/^4@.)O\ L\6<_P#K:XD_/LR_Y+/'_P#93XK_ -6M0_R):_VL*_Q3
MZ_VL*_J+Z=G_ #:S_N]__?0/T'Q>_P":>_[JW_O,"O\ (E_X*4_\I&/V_/\
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M15>?/M_\'$G_ "AT_;!_[M^_]:D^"5?YZ/\ P36_Y2,?L!_]GK?LK_\ J]/
ME?Z%W_!Q)_RAT_;!_P"[?O\ UJ3X)5_GH_\ !-;_ )2,?L!_]GK?LK_^KT\"
M4_HI?\F \1?^RAXN_P#6+X='X=?\D9GG_8;F?_JJP)_KM5\4_P#!2G_E'/\
MM^?]F4_M4?\ JB_'=?:U?%/_  4I_P"4<_[?G_9E/[5'_JB_'=?Y]\(_\E7P
MQ_V4.2_^K+#'XOEO_(QP'_8;A?\ T_3/\B6O]K"O\4^O]K"O[C^G9_S:S_N]
M_P#WT#];\7O^:>_[JW_O,"O\B7_@I3_RD8_;\_[/6_:H_P#5Z>.Z_P!=JO\
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MW@G0K_Q+XGUC^RM#L=3UO4_[,T33+Z]_L_1]-U#5+WR/LVGV-W=R0P2?GG\
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MI\\G!-1A;7F=HVZGZY4445_FB?@P4444 %%%% !1110 4444 %%%% !1110
M5_E]_P#$.W_P6+_Z,^_\V!_9;_\ GVU_J"45^Q>$_C;Q7X.?V_\ ZLY?P_CO
M]8_[*^O?V[A,RQ7LO[(_M+ZM]5_L_-LKY.?^U,1[?VWM^;DH^S]ERS]I]/PY
MQ9F/#'USZA1P5;Z]]7]K]<IUZG+]6]O[/V?L<3A[7^L3Y^;GO:-N6SYOR^_X
M(R?L[?&/]D__ ()K?LW_   ^/_@__A ?BWX!_P"%P_\ "6>$_P#A(/"WBG^R
M?^$I^/?Q2\::#_Q/O!6M^(_#-_\ ;O#/B/1M2_XENLWGV7[9]CO/L^H6]U:P
M?4/[;_P[\9?%_P#8M_:]^$OPZT?_ (2'X@_%']E_X_?#KP+H']H:7I/]N>,?
M&WPH\6>&O#&C_P!JZY?:9HFF?VGK>IV-E_:&L:EI^EV7G_:=0OK2TCFGC^H*
M*^"S'BG,,SXPQW&U>C@X9KF'$N)XIK8>C3KQR^.88O-)YM4HTJ4\14Q,<''$
MU'"%.>+G75!*,L1*I>H_'KYA7Q&9ULUG&DL16Q]3,)0C&:HJM4Q#Q,HQBYRF
MJ2G)I1=1SY-'-OWC_+[_ .(=O_@L7_T9]_YL#^RW_P#/MK_4$HHK[WQ8\;>*
M_&/^P/\ 6;+^'\#_ *N?VK]1_L+"9EA?:_VO_9OUGZU_:&;9IS\G]EX?V'L?
M8<O/6]I[7FA[/V.(^+,QXG^I_7Z."H_4?K'LOJ=.O3YOK/L/:>T]MB<1>WU>
M')R\EKROS77*5_G.?MO_ /!!_P#X*M?%_P#;2_:]^+7PZ_96_P"$A^'WQ1_:
MA^/WQ%\"Z_\ \+Q_9PTG^W/!WC;XK^+/$OAC6/[*USXOZ9K>F?VGHFIV-[_9
M^L:;I^J67G_9M0L;2[CF@C_T8Z*XO"KQ?XE\(,PS7,N&L#D>.KYQ@Z.!Q,,\
MPV/Q-*%*A7]O"5". S/+)QJ.>DG4J58N.B@GJ9<.\38_AFMB:^ HX2M/%4H4
MJBQ=.M4BHPGSIP5'$8=J5]W)R5NBW/\ +[_XAV_^"Q?_ $9]_P"; _LM_P#S
M[:_LC_:]_8Q_:4^*/_! 7PG^Q/X%^&_]N?M.:9^R_P#L0?#J^^&?_"8> M,\
MCQC\(/$GP!O_ (BZ/_PF>L>*=/\ A])_PCUIX)\3R_VA#XKDTO5O[,\O0[[4
MY;W3TN_WAHK['C/Z2O'7'.8<&YEFV4\)8>OP/Q)@N*<IAEV SBC2Q&88&OAZ
M]*CF,<3GV+G5P<IX:"J4\-4PE=Q<U'$0;3CZF:<>9QF];*Z^)PV6PGE./I9A
MAE0HXJ,9UJ,X3C&NJF,JN5)N"YHTW3FTW::T:_RJOBU_P0Y_X*P?!;P[9>*?
M&'[%'Q1UG3-0UJWT""U^$NH^!?CYXBCOKJQU'48Y[WP?\"O%WQ&\6Z9HJV^E
MW,=QXEU'1+7P[:7TNG:7=ZK!J>L:1:7S?A+_ ,$//^"K_P :M O_ !+X._8G
M^*>C:=INL2Z'<6WQ:OO!'P"U^2]ALK&_>>P\)_';Q9\./%.JZ.T&HV\<7B'2
M]&O- N+V.^TV#4Y-1TS4K6T_U5Z*_2?^)W?$7ZE[/_5;@K^T?:7^M>PSWZE[
M*_P?4/[:]O[2VGM?[2Y;Z^QMH>[_ ,19SSV5O[.RKV_-_$Y,9[+E[>Q^M\_-
M_>]O;^[T/X]_^"<7_!K;8_!WXJ:%\8_V^_B#\+_C3;^!];O-1\,_L]?#;3_$
M?B'X5^*KZSAT*Y\*>(_BEXO\<:)X,U/Q+HFGZFWB-M6^#<?P]C\.>(IM.\*W
M'B?QKXC\(WWB_P"&>K?V$445_-?'WB3QCXF9K1S;B_-99A6PM&6'P.&I4:6$
MP&7T)RYZD,'@\/&%&G*M-1=>O)3Q6(]G1C7KU(T*,:?PF<Y]FF?XB.)S/$.M
M*G%PHTXQC3HT8-WDJ5*"48N32<YN]2=HJ<Y*$5'\OO\ @LW^SM\8_P!K#_@F
MM^TA\ /@!X/_ .$^^+?C[_A3W_")^$_^$@\+>%O[6_X1;X]_"WQIKW_$^\:Z
MWX<\,V'V'PSX<UG4O^)EK-G]J^Q_8[/[1J%Q:VL_\;O[$'_!!_\ X*M?"#]M
M+]D+XM?$7]E;_A'OA]\+OVH?@#\1?'6O_P#"\?V<-6_L/P=X)^*_A/Q+XGUC
M^RM#^+^IZWJ?]F:)IE]>_P!GZ/INH:I>^1]FT^QN[N2&"3_1CHK[/P^\>^,/
M#?@_.N"LCRWAK%95GN,S''8O$9M@\TKYA3JYGE>"RG$1PU7!YQ@<-"G##8&C
M.BJN$K2C7E4E.=2FXTX>IDO&.9Y%EF*RK"4,!4P^,JUZM6>)I8B=:,L1AZ6&
MFH2I8JC!14*,7%2IR:FY-N2:BBOE_P#;?^'?C+XO_L6_M>_"7X=:/_PD/Q!^
M*/[+_P ?OAUX%T#^T-+TG^W/&/C;X4>+/#7AC1_[5UR^TS1-,_M/6]3L;+^T
M-8U+3]+LO/\ M.H7UI:1S3Q_4%%?CN78ZMEF88#,J$:<Z^7XS"XZC"LI2I2J
MX2O"O3C5C"=.<J<ITTIJ%2$G%M1G%V:^8H5I8>M1KP47.C5IU8J2;BY4YJ<5
M))IN+:5TFG;9K<_R^_\ B';_ ."Q?_1GW_FP/[+?_P ^VO\ 4$HHK]6\6/&W
MBOQC_L#_ %FR_A_ _P"KG]J_4?["PF987VO]K_V;]9^M?VAFV:<_)_9>']A[
M'V'+SUO:>UYH>S^BXCXLS'B?ZG]?HX*C]1^L>R^ITZ]/F^L^P]I[3VV)Q%[?
M5X<G+R6O*_-=<I7^<Y^V_P#\$'_^"K7Q?_;2_:]^+7PZ_96_X2'X??%']J'X
M_?$7P+K_ /PO']G#2?[<\'>-OBOXL\2^&-8_LK7/B_IFMZ9_:>B:G8WO]GZQ
MINGZI9>?]FU"QM+N.:"/_1CHKB\*O%_B7P@S#-<RX:P.1XZOG&#HX'$PSS#8
M_$TH4J%?V\)4(X#,\LG&HYZ2=2I5BXZ*">IEP[Q-C^&:V)KX"CA*T\52A2J+
M%TZU2*C"?.G!4<1AVI7W<G)6Z+<_R^_^(=O_ (+%_P#1GW_FP/[+?_S[:_T9
M/V(/AWXR^$'[%O[(7PE^(NC_ /"/?$'X7?LO_ 'X=>.M _M#2]6_L/QCX)^%
M'A/PUXGT?^U=#OM3T34_[,UO3+ZR_M#1]2U#2[WR/M.GWUW:20SR?4%%>SXJ
M^/7&'B_E^4Y=Q+EO#>!H9/C*^-PT\CP>:8:K.K7HJA.->6/SC,X2IJ"O%4X4
MI*6KFUH=7$7&.9\34<-0Q]# 4886K.K3>$I8BG)RG#D:FZV*Q"<;;**B[]7L
M?Q[_ /!1W_@UML?C#\5->^,?[ GQ ^%_P6M_'&MV>H^)OV>OB3I_B/P]\*_"
MM_>0Z[<^*_$7PM\7^!]%\9ZGX:T34=37PXVD_!N7X>OX<\.S:CXJN/#'C7PW
MX1L?"'PSTG^;#XM?\$//^"KWP5T"P\2^,?V)_BGK.G:EK$6AV]M\);WP1\?=
M?CO9K*^OTGO_  I\"?%GQ'\4Z5HX@T^>.7Q#JFC6>@07LECIL^IQZCJ>FVMW
M_JKT5]KP9]+CQ3X4P.$RK'?V/Q9@,'3H8>E4SW#8G^UH87#PE"%*.:8'%X65
M>HXN"GBLRP^8XF?LXN51SE4E/U<K\2N(<NHTL/5^JYC1I1A"+QE.I]95."<5
M%8BC4IN<FK7J5X5YOE3<FVV_\JCX2_\ !#S_ (*O?&K0+_Q+X._8G^*>C:=I
MNL2Z'<6WQ:O?!'P"U^2]ALK&_>>P\*?';Q9\./%.JZ.8-0@CB\0Z7HUYH$][
M'?:;!J<FHZ9J5K:?T6_\$9?^#?G]L']D/]L+X'?MD?M'>,_@YX0T;X=^$?'^
MK#X2^$]>USQY\2O^$M^('PW\1_#2'P?XJO+/0M*^'.AV^AZ?XWUC7]3\2^$O
M'?Q&M)M3\/:?X>TVPO;'Q#<>*/#W]E5%5QK]+?Q)XPR?..'HY?PQDF49U@<=
ME>,6!P&,Q.85,MS'"U,'B\-/%YAC\3AU*I0JU8*OA\!AJT.?FIRC.,9)YKXD
MY[FF%Q6"5' 83#8JC6P]54:-6I6E0KTW2J4W5K5JD+RA*2YX4:<E>Z::3"OX
M4?\ @HI_P:T?%CPWXF\2_$W_ ()UZUI?Q)\":[XAO=0L_P!FCQOK]CX4\>_#
MO3=1F\/QV>A^!OBCXW\0IX6^)/A[3+R\\57OG?$/6_ /BOPWX0TCP[I$NL?%
M_P 776IZ_<?W745^0^&OBMQEX4YKB,TX2QU&G#'1H4\URO'X?ZWE6;4L-*I/
M#4\;AU.C7C+#SK5G0Q."Q.$QM&-:O2I8F%'$XBG5^9R+B+-.'<1/$9;6C%5E
M".(P]:'M,/B8TW)PC5A>,DX.4N2I2G2JP4YQC44:DXR_RA+#_@C/_P %2]1^
M+C_!.W_8=^.\?C*.\U&P;6K_ ,-6^E_",SZ7HUUKMRZ?M :G?VGP'ELY;*TE
M@T[48_B0^GZQK+VOAW2;J]\07MEIEQ_1'_P26_X-G_&7A7XC>'OV@/\ @I5H
M'@J31/"FS6/!?[*-GK^E^//[9\8Z?KNJVEK??'_5-!&I_#[4_!6F6FF:5XIT
M;X=>$/%'C;2_B%_;^FV/Q-U#1-$\/>+?A?XY_M8HK]DXQ^E[XF\4Y+7R3 X7
M(^%J>.P<,-C\QR6GF']KSE*,X8OZCC,5CZT,NH8F$E&*I8>IF&%Y7*AF:G)2
MC]1F?B9G^8826$I4\)EZJTE"M7PD:ZQ+;357V-2I6FJ$*B:2482KT[7CB+NZ
M_P YS]M__@@__P %6OB_^VE^U[\6OAU^RM_PD/P^^*/[4/Q^^(O@77_^%X_L
MX:3_ &YX.\;?%?Q9XE\,:Q_96N?%_3-;TS^T]$U.QO?[/UC3=/U2R\_[-J%C
M:7<<T$?E/PI_X-G_ /@K'\0_$TV@^+OA/\-/@1I<6DW6HIXT^*WQL^'VL>&;
MB\M[BSABT&&U^!^J_&7QBNK7T=S-=VLUQX3@T-+?3KQ;W6K.Z?3[:^_TN:*V
MPWTQ_%/!93A<HP>5<$8>G@L#AL!AL7'*LYJ8R%/"T:="E5?M^(JN$G6<*:<W
M/"2I.3DU22LE</%#B&EAJ>&I8?*8*E1IT855AL5*JHTXQA&7OXV5)R:CK>FX
MW;M%:6****_DX_. HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 18, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 18,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSMED INCORPORATED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001104506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">54-1972729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 US Highway 202/206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">977-9900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INSM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20059077_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://insmed.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20059077_8k.htm">ef20059077_8k.htm</File>
    <File>insm-20251118.xsd</File>
    <File>insm-20251118_lab.xml</File>
    <File>insm-20251118_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20059077_8k.htm": {
   "nsprefix": "insm",
   "nsuri": "http://insmed.com/20251118",
   "dts": {
    "inline": {
     "local": [
      "ef20059077_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "insm-20251118.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "insm-20251118_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "insm-20251118_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://insmed.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20251118to20251118",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20059077_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20251118to20251118",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20059077_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001140361-25-042598-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-042598-xbrl.zip
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MXA&-WN\3>3\-_BUZ1%/'V3[!/A4:!M=1CX3"ARLL#N.D1WY3Y=\^\2C[?IV
M=G&EO.7+OWV8A0,>W)  IO[3Y?E)@,;A]X!S$;5*@GB0CD,*Q$1Q).")@^"N
MAX2+)#^4K>4A-#@%AB<!(Q$=X:,BZ!W!#'"<A9.07K?DFTXHR_[I4Y6I5E=P
MIJNF:0BJ49WZS'$\00W?,PJNW647*,"L%*XLOA>SW'Y]:('-Z_G!G># MQ <
MS*'\[Z!3(VDUA<<1R-RT#R0F-!Q$7-S](:852C7#X2KCNBH,US0UWW,<US5=
MW>;,\QV-/4[I(4R#IJFFI787J.K4>9@(7Z!-$^GA ;K 7BJ=&W1-I$OL#1-\
M"ZJ=4O;?ODMYJ[B-INU#*PU&XU" D,GNJWW*TS2>)/),NOA>0;X<\5+RBW9"
M,JH\"SB>^X%(B*11+/4Y_<$?]>'//WQ87JKW/@;NQ+P\ \>>9)] AP^1*$73
M%,TIG[N_-R.3KVA:WBG/RY=T:GPHF3;C4J<B\1U0ET)I"OU GZH,!=J)'@FB
M( .;M)^;-VQ[D(YI5%/NBO*V#LE!!QN4'9=/Y69EF)0/>G$"KR]TD.1GBA=G
M63R"KL9W)(W#@!,O!%6?W<_B<8^8\S=+4H& NWM;41B$!VQ%S=" 3<Y$LD]&
M-+D.(@7M3H_021;/+B7Y6^0UM'9R0+.AY<?EZ);UO(X=--$.R@NWQ>"\..3
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M?9:_)-K!'_^5/P:<C<+#_P-02P,$%     @ ^8%R6W3EK;68'0  Q'4  !4
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MNG55'X"42T6@ C-U!Z4!72^PI@TJ;=-_)4U!GT+W8>X^4*MMR"38R!.@,OI
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M GLL^5T(VF6<R\SD*#Z"/6ZA?MHL<T=P\M>6N7':M1$20WQ!_J?QV>M>UE+
M1H><3;%]1*L*1;_SD,33++._;-+-:<C^$IN6L  R8Q7CAGY(KU/X!YJ#.J)L
M;%@=/+2$]@E7;+-U3<'?]8RVA4[IYP#6_/;8MWS/SP@)N)^$8V"J ,KJ85R3
M[[$[8'-_=_^Q>CK8[NUN[6S=<5-8_3*VR^L7;GG_[1?*Z@>WSX1.]ES3\OP]
M]12F&B'%VSJ94N7P^XKCD6LD87];IRYRNF.A?+J_#:'<W>[M/QT\NW.AY ,)
M_Z@<?NYK+Q;Y';_/^;4APK?[?<[.SV,VG]VGYT_HYT[Y@_WMUO\#4$L#!!0
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M]>S]QW)(S-^0]ENNA=CAJ"*[_@-02P,$%     @ ^8%R6TZX63)["   ,58
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M9!MB>3V1K?LT/H^M2J?E'T3NT6C\T^QG) 1[?B+;5!%BSZ*,H*K:/(O=5-
M"%Z2.QKQ%];=/B]G) 4>N;,HZFF!"@\6+1%]<(3=FHB$U--+@NI65#5WX,$\
M6WU(8T)E,@&A@-.ER 'XE((JK("V>D**S8-&,(H/AZI#$X&R;BJ#MU_FX,P3
M2\)DSB2)(,Q>LH"7W[-U_, *@($'-6P2Y3(L2UJX%$,QV[@<*WZ;+LF2?"I:
MD6CNP(,:UB*1YJ3"5^==I7J%AFJ]FX,+]HF_M;5N2JJWG$[_!U!+ P04
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M/T3$'_$3[4__ U!+ 0(4 Q0    ( /F!<EOR@KUMDA,  *=]   1
M      "  0    !E9C(P,#4Y,#<W7SAK+FAT;5!+ 0(4 Q0    ( /F!<EMT
MY:VUF!T  ,1U   5              "  <$3  !E9C(P,#4Y,#<W7V5X.3DM
M,2YH=&U02P$"% ,4    " #Y@7);4RD0R$(#   T#P  $0
M@ &,,0  :6YS;2TR,#(U,3$Q."YX<V102P$"% ,4    " #Y@7);3KA9,GL(
M   Q5@  %0              @ ']-   :6YS;2TR,#(U,3$Q.%]L86(N>&UL
M4$L! A0#%     @ ^8%R6\1;:@+9!0  [CX  !4              ( !JST
L &EN<VTM,C R-3$Q,3A?<')E+GAM;%!+!08     !0 % $<!  "W0P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ef20059077_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="insm-20251118.xsd" xlink:type="simple"/>
    <context id="c20251118to20251118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2025-11-18</startDate>
            <endDate>2025-11-18</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20251118to20251118"
      id="Fact_fa0c056edc20443ea1a2afc88bea3fb3">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20251118to20251118"
      id="Fact_138d0cd20e39441fb88994927dcbf81c">0001104506</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20251118to20251118"
      id="Fact_f3020859e4854f34943dbba5137bd84f">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20251118to20251118"
      id="Fact_f635d152cf594bb4acd885577dd7bf6b">2025-11-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20251118to20251118"
      id="Fact_7784286cc4df42c5991bacd653ccd847">INSMED INCORPORATED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20251118to20251118"
      id="Fact_9ddc2809e82044638c4cb24989f0e675">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20251118to20251118"
      id="Fact_75c397c825214611ba353488c2ff590d">000-30739</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20251118to20251118"
      id="Fact_379287efcb8445e887ebbacd57af7fda">54-1972729</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20251118to20251118"
      id="Fact_aa46f54c87b843558e6f5274bef11c60">700 US Highway 202/206</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20251118to20251118"
      id="Fact_88d65d06043f44f1bbf38c35f868ef2d">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20251118to20251118"
      id="Fact_7dbcb8eac36f499cb21bdecaf5cbf80c">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20251118to20251118"
      id="Fact_9291b8900c2e4f76af739461c54d03b5">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20251118to20251118"
      id="Fact_5e7af2288a304fe3bb16995635b2b933">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20251118to20251118"
      id="Fact_bfb31c89a7f64ab39325eadc00f7d5c2">977-9900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20251118to20251118"
      id="Fact_172a2f3b8af84dbc85d95733441b22db">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20251118to20251118"
      id="Fact_0d88d05879e94794b3d75b729407ab28">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20251118to20251118"
      id="Fact_ac55bbd420e94d75bdcfe80c7d7efd60">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20251118to20251118"
      id="Fact_07139530014e43ca9b7f1a538946156e">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20251118to20251118"
      id="Fact_d9950c6192464551bbf3336e17e83eda">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20251118to20251118"
      id="Fact_4e8c083707934900b5b0afa02760b972">INSM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20251118to20251118"
      id="Fact_173ca36f8adc4617a9501de7067f0159">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20251118to20251118"
      id="Fact_ea60a5c1c3254819a39bfb354eabd8bd">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
